Umecrine Cognition Receives Significant Financial Support
Karolinska Development AB today announced that its portfolio company, Umecrine Cognition, successfully raised SEK 23.8 million through a convertible loan. This funding is essential for the continuation of clinical trials focused on golexanolone for patients suffering from primary biliary cholangitis (PBC).
Ongoing Clinical Study of Golexanolone
Currently, Umecrine Cognition is actively recruiting participants for the second phase of its Phase 1b/2 clinical study. This study aims to gather a total of 84 patients across more than 30 sites in various international locations. Preliminary results from the initial study phase indicated that golexanolone is safe and well-tolerated, with only minor adverse effects reported. Key outcomes also suggested that the treatment can achieve significant drug exposure levels, alongside favorable results on anxiety and depression scales.
Investor Support and Future Goals
The convertible loan is backed by an investor consortium, which notably includes Karolinska Development, along with AB Ility and Ribbskottet AB. The financing secured from this consortium will be utilized not only for the ongoing clinical trial expenses but also to support operational costs throughout the coming year. Completion of this pivotal study is anticipated in the first half of 2025, marking a crucial step in the advancement of golexanolone.
Strategic Importance of the Financial Injection
Viktor Drvota, the CEO of Karolinska Development, highlighted the significance of this funding, stating, "After the initial study yielded promising results, Umecrine Cognition is poised to embark on the final and critical phase of this clinical trial, which could greatly enhance the project's value and benefits for patients. With the strengthened financial backing, the company is in a prime position to continue its valuable work with golexanolone, addressing a critical medical need."
Karolinska Development's Ownership Influence
As a major stakeholder, Karolinska Development holds a 73% ownership stake in Umecrine Cognition. Yet, with the full exercise of share options linked to the convertible loan, this percentage will decrease to 62%. This shift underscores the dynamic nature of investments and strategic partnerships in the life sciences sector.
About Karolinska Development
Karolinska Development AB is a prominent Nordic life sciences investment firm, primarily focused on identifying and fostering groundbreaking medical innovations within the region. The company concentrates on creating and nurturing enterprises that advance significant medical assets into market-ready products aimed at improving patients' lives while delivering a favorable return to shareholders.
Commitment to Innovation
Access to cutting-edge medical innovations from the Karolinska Institutet and prestigious universities throughout the Nordic region allows Karolinska Development to position itself at the forefront of medical advancements. The firm’s goal is to cultivate relationships around leading scientists, backed by experienced management teams and specialized international investors, to optimize success rates.
Diverse Portfolio
Karolinska Development boasts a robust portfolio comprising eleven companies, all targeting innovative treatments for critical and debilitating ailments. This portfolio strategy reflects the company's commitment to addressing significant medical challenges while ensuring sustainable growth.
Frequently Asked Questions
What is Umecrine Cognition focused on currently?
Umecrine Cognition is concentrating on continuing clinical studies of golexanolone, a medication for treating primary biliary cholangitis.
How much funding did Umecrine Cognition raise?
The company raised SEK 23.8 million through a convertible loan for its clinical trials.
What were the initial results of the clinical study?
The initial results showed that golexanolone was well-tolerated and safe, with minor adverse events recorded.
Who are the key investors in this funding round?
The funding was supported by an investor consortium including Karolinska Development, AB Ility, and Ribbskottet AB.
What proportion of Umecrine Cognition does Karolinska Development own?
Karolinska Development currently owns 73% of Umecrine Cognition, which may decrease to 62% with the full exercise of share options.
